Silence Therapeutics (SLN) Total Current Liabilities (2018 - 2026)

Silence Therapeutics has disclosed Total Current Liabilities across 9 years of filings, most recently posting $10.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $10.5 million, down 45.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.5 million (down 45.7% YoY), and the FY2025 annual result was $13.6 million, down 19.08% from the prior year.
• Total Current Liabilities came in at $10.5 million for Q1 2026 at Silence Therapeutics, down from $13.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $25.7 million in Q4 2022 to a low of $10.5 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $17.1 million (2024), against an average of $17.5 million.
• Across the five-year window, Total Current Liabilities gained 25.89% in 2022 and tumbled 45.7% in 2026, its largest moves.
• Silence Therapeutics' Total Current Liabilities stood at $25.7 million in 2022, then retreated by 14.31% to $22.1 million in 2023, then declined by 23.72% to $16.8 million in 2024, then retreated by 19.08% to $13.6 million in 2025, then dropped by 23.16% to $10.5 million in 2026.
• The last three Total Current Liabilities figures came in at $10.5 million (Q1 2026), $13.6 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.